21 September 2021 - Today, the U.S. FDA authorised marketing of software to assist medical professionals who examine body tissues (pathologists) in the detection of areas that are suspicious for cancer as an adjunct to the review of digitally scanned slide images from prostate biopsies. 

The software, called Paige Prostate, is the first artificial intelligence based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harbouring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.

Read FDA press release